Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page footer/site release label has been updated from revision v3.5.2 to v3.5.3, reflecting a website software update rather than any change to the study record itself.
    Difference
    0.0%
    Check dated 2026-04-24T05:54:51.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2; Deleted Revision: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-17T02:40:08.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    47 days ago
    Change Detected
    Summary
    A new page revision v3.5.0 was added and the previous revision v3.4.3 was removed.
    Difference
    0.0%
    Check dated 2026-03-19T04:52:01.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now displayed, replacing the previous v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T00:54:55.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the funding-status notice and Revision: v3.4.1 text.
    Difference
    0.4%
    Check dated 2026-02-11T14:33:08.000Z thumbnail image
  8. Check
    90 days ago
    Change Detected
    Summary
    Added a site-wide notice about a funding lapse and NIH Clinical Center operations, and updated the page version from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:42:45.000Z thumbnail image

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.